RARoberta Angioni

Roberta Angioni

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Roberta Angioni has a total of 33 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Bioinspired TIMP-1 Nanoparticles Mimic Extracellular Vesicle Anti-angiogenic Activity in Ewing Sarcoma

    by Cristina Liboni, Martina Boaron, Diana Corallo, Sanja Aveic, Marco Ballestri, Ricardo Sánchez-Rodríguez, Alessandra Maria Testa, Claudia Ferroni, Greta Varchi, Antonella Viola, et al.

    Anti-angiogenic therapies targeting the vascular endothelial growth factor (VEGF) axis have achieved transient benefits, as tumors rapidly activate compensatory vascular programs. Here, we present a bioinspired nanoplatform that reproduces the anti-angiogenic signaling of mesenchymal-stromal-cell-derived extracellular vesicles (EVs) by delivering the endogenous metalloproteinase inhibitor tissue inhibitor of metalloproteinases-1 (TIMP-1). Poly(methyl methacrylate) nanoparticles (NP_TIMP1) were engineered to retain TIMP-1 bioactivity, inhibit matrix metalloproteinase activity, and efficiently interact with endothelial cells. In vitro, NP_TIMP1 suppressed endothelial sprouting and tip-cell formation in 2-dimensional and 3-dimensional microfluidic systems. In zebrafish patient-derived xenografts of Ewing sarcoma, NP_TIMP1 localized to tumor-associated vessels and substantially reduced vascular infiltration, reproducing the efficacy of TIMP-1-enriched EVs. In contrast, soluble TIMP-1 failed to elicit these effects, indicating that nanoparticle-mediated delivery enhances protein stability and spatial engagement with the endothelium. This study establishes TIMP-1 as a key stromal regulator of angiogenesis and demonstrates that EV-mimetic nanoparticles can recapitulate its therapeutic potential, providing a scalable bioengineering approach to overcome the limitations of natural vesicles and develop next-generation anti-angiogenic nanotherapeutics.

  • Open Access

    RAGE engagement by SARS-CoV-2 enables monocyte infection and underlies COVID-19 severity

    by R. Angioni, M. Bonfanti, N. Caporale, R. Sánchez-Rodríguez, F. Munari, A. Savino, D. Buratto, I. Pagani, N. Bertoldi, C. Zanon, et al.

    The spread of SARS-CoV-2 has fueled the COVID-19 pandemic with its enduring medical and socioeconomic challenges due to subsequent waves and long-term consequences of great concern. Here we charted the molecular basis of COVID-19 pathogenesis, by analysing patients’ immune response at single-cell resolution across disease course and severity. This approach uncovered cell subpopulation-specific dysregulation in COVID-19 across disease course and severity and identified a severity-associated activation of the receptor for advanced glycation endproduct (RAGE) pathway in monocytes. In vitro experiments confirmed that monocytes bind the SARS-CoV-2 S1-RBD via RAGE and that RAGE-Spike interactions drive monocyte infection. Our results demonstrate that RAGE is a novel functional receptor of SARS-CoV-2 contributing to COVID-19 severity. One-Sentence Summary: Monocyte SARS-CoV-2 infection via the receptor for advanced glycation endproduct triggers severe COVID-19.